Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Glioblastoma 203Brain Neoplasms 94Gliosarcoma 93Glioma 88Central Nervous System Neoplasms 78Astrocytoma 66Oligodendroglioma 45Melanoma 37Medulloblastoma 18Neuroblastoma 17Neoplasm Metastasis 14Ependymoma 13Neoplasms 10Choroid Plexus Neoplasms 10Sarcoma 9Recurrence 9Optic Nerve Glioma 9Familial ependymoma 9Carcinoma, Non-Small-Cell Lung 9Ovarian Neoplasms 8Lung Neoplasms 8Spinal Cord Neoplasms 7Breast Neoplasms 7Uveal Melanoma 6Sarcoma, Ewing 6Rhabdoid Tumor 6Pinealoma 6Neuroectodermal Tumors, Primitive 6Unspecified Adult Solid Tumor, Protocol Specific 5Small Cell Lung Carcinoma 5

Interventions

Amifostine 12Cisplatin 10Radiotherapy 8Etoposide 8Cyclophosphamide 5Paclitaxel 4Filgrastim 4Gemcitabine 3Cytarabine 3Carboplatin 3denileukin diftitox 2apatinib 2Vincristine 2Pyridoxine 2Irinotecan 2Ifosfamide 2Fibroblast Growth Factor 7 2Epoetin Alfa 2Doxorubicin 2Dexamethasone 2Chemotherapy, Adjuvant 2Bleomycin 2uridine triacetate 1sargramostim 1peginterferon alfa-2b 1pegfilgrastim 1pegaspargase 1eribulin 1camrelizumab 1Vitamin E 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Drug-Related Side Effects and Adverse Reactions × Temozolomide × Clear all
NCT00093353 2026-04-14

N2003-01: Irinotecan, Temozolomide, and Cefixime in Treating Young Patients With Recurrent or Resistant Neuroblastoma

New Approaches to Neuroblastoma Therapy Consortium

Phase 1 Completed
30 enrolled
CNS

Diarrhea, Neuroblastoma, Drug-Related Side Effects and Adverse Reactions

Data powered by HemOnc (CC BY 4.0) Colophon âš¡